9.21 USD
▼+0.13-0.32%
盘后 9.27 +0.27%
2026-08-03
市值
$96.71M
市盈率
—
EPS
-13.35
股息率
—
52 周区间
6.01 – 17.44
成交量
95.39K
Beta
1.59
目标价
34.83
52W 低 6.0152W 高 17.44
价格走势
公司简介
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in ...